Immune response of booster dose with ChAdOx-1 in adult who had received 2 doses of CoronaVac (COVID-19)
Phase 2
Recruiting
- Conditions
- Prevention of COVID-19 with booster-dose strategy among healthy adult who received 2-dose of Coronavac using ChAdOx1 nCoV-19 vaccine.COVID-19 Vaccine, AstraZeneca Booster , Fractional low dose vaccine
- Registration Number
- TCTR20210722003
- Lead Sponsor
- Health and Aging Platform, Chulalongkorn University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
1. Age 18-59 years
2. Have a history of receiving two doses of CoronaVac vaccine with 21-28 days apart.
3. Post-second dose of CoronaVac vaccine for more than 60-180 days on day of participation in study
Exclusion Criteria
1. Received immunosuppressants within 3 months prior to participation in the study
2. Received blood or blood products within 3 months prior to participation in the study
3. Received any vaccinations within 2 weeks prior to participation in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Anti-S-RBD Antibody level day 0 and 14 after vaccination BIOTEC COVID-19 IgG ELISA , sVNT for neutralizing antibody day 0 and 14 after vaccination ELISA (GenScript USA),Antigen-specific cellular immunity day 0 and 14 after vaccination ELISA
- Secondary Outcome Measures
Name Time Method Reactogenicity and adverse events Day1, Day 14 Prevalence,Anti-S-RBD Antibody level day 0 and 90 after vaccination BIOTEC COVID-19 IgG ELISA,sVNT for neutralizing antibody day 0 and 90 after vaccination ELISA (GenScript USA),Antigen-specific cellular immunity day 0 and 90 after vaccination ELISA